Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Estimated Small Dense LDL Cholesterol and Coronary Artery Disease in Familial Hypercholesterolemia.

Created on 26 Oct 2026

Authors

Dimitrios Delialis, Christos V Rizos, Evmorfia Aivalioti, Chrysoula Moustou, George Liamis, Ioannis Skoumas, George Sfikas, Genovefa Kolovou, Loukianos Rallidis, Anastasia Garoufi, Konstantinos Tziomalos, Emmanouil Skalidis, Vasileios Kotsis, Evgenia Mavrokefalou, Michalis Doumas, Vaia Lambadiari, Panagiotis Anagnostis, Theodosios Filippatos, Amalia Boufidou, Vasiliki Giannakopoulou, Georgia Anastasiou, Spyridon Spantidakis, Charalambos Vlachopoulos, Ioanna Dima, Charalambos Koumaras, Elisavet Prodromiadou, Vana Kolovou, Georgios Fakas, Konstantinos A Papathanasiou, Achilleas Attilakos, Dimitrios Agapakis, Evangelos Zacharis, Christina Antza, Aspasia Antonopoulou, Chrysoula Boutari, Aikaterini Kountouri, Maria Pappa, Evangelia Koukou, Eleni Mpellou, Evangelos Liberopoulos, Kimon Stamatelopoulos

Published in

Journal of atherosclerosis and thrombosis. Oct 24, 2026. Epub Oct 24, 2026.

Abstract

Recent evidence reports good agreement between measured and estimated small-dense low-density lipoprotein cholesterol (EsdLDL-C) using a readily applicable formula. Its clinical utility in heterozygous familial hypercholesterolemia (HeFH) has not yet been evaluated. We aimed to evaluate the sex-specific associations of pre-treatment EsdLDL-C with coronary artery disease (CAD) prevalence in adult patients with HeFH and its discriminative value beyond LDL-C.
Data from consecutively recruited adults with a clinical diagnosis of HeFH from an ongoing registry (HELLAS-FH, n = 3,276) were analyzed. Patient demographics, lipid parameters, CAD risk factors, and CAD prevalence at registry enrollment were evaluated. EsdLDL-C was calculated at pre-treatment (i.e., before any hypolipidemic therapy initiation) using the Sampson equation.
EsdLDL-C was associated with an increased prevalence of type 2 diabetes and hypertension, a higher body mass index and triglycerides, and lower high-density lipoprotein cholesterol. EsdLDL-C was also the strongest independent lipid-associated factor for CAD (OR: 1.24, p<0.001). This association was more pronounced in women (OR 1.57, p<0.001). EsdLDL-C showed higher CAD discrimination than LDL-C (AUC 0.611 vs. 0.522). Incorporating EsdLDL-C into the best discriminative model improved discriminative ability vs the core model (AUC 0.831 vs 0.828, p = 0.038) and overall model fit (ΔAIC) = -10.3). This incremental predictive value was driven predominantly by females (ΔAIC = -14.1; AUC 0.787 vs 0.769, p = 0.015).
In a large sample of patients with clinical HeFH, EsdLDL-C was incrementally associated with CAD beyond LDL-C. This finding was more pronounced in women. The clinical utility of this readily available lipid marker as a risk enhancer should therefore be further investigated.

PMID:
42927934
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 25
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement